Patents Issued in February 22, 2018
  • Publication number: 20180050061
    Abstract: The present invention relates to roneparstat for use in a combined therapy for the treatment of multiple myeloma. In particular it has unexpectedly been found that the combined use of roneparstat with a proteasome inhibitor, in particular selected between bortezomib and carfilzomib or with melphalan improve efficacy in decreasing the overall tumor burden, especially showing synergism, with respect to the administration of each active ingredient alone.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 22, 2018
    Inventors: Ralph D. Sanderson, Vishnu Prakash C. Ramani, Alessandro Noseda, Paola Barbieri
  • Publication number: 20180050062
    Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. The dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one magnesium salt, and optionally potassium salt, and calcium salt. According to the invention the glucose and the at least one magnesium salt, are present as anhydrous components in the dialysis acid precursor composition.
    Type: Application
    Filed: November 1, 2017
    Publication date: February 22, 2018
    Inventors: Ola CARLSSON, Lennart JONSSON, Torbjorn LINDEN, Anders WIESLANDER
  • Publication number: 20180050063
    Abstract: Methods of inducing a polarization of macrophages. The method includes obtaining a blood fraction, fractionating the blood fraction to produce a blood fraction, and contacting the blood fraction with a source of macrophages. A blood fraction including platelet-poor plasma polarizes the source of macrophages into M1 macrophages. A blood faction including a protein solution polarizes the source of macrophages into M2 macrophages.
    Type: Application
    Filed: October 30, 2017
    Publication date: February 22, 2018
    Inventors: Jennifer E. Woodell-May, Joel C. Higgins, William King
  • Publication number: 20180050064
    Abstract: The invention relates to a method for producing eye drops, the thus obtained eye drops and to a kit which comprises the eye drops.
    Type: Application
    Filed: March 22, 2016
    Publication date: February 22, 2018
    Inventors: Marc SCHROTT, Andrea JOCHHEIM-RICHTER
  • Publication number: 20180050065
    Abstract: The present invention provides a chimeric antigen-receptor (CAR)-forming polypeptide comprising: (i) an antigen-binding domain; (ii) a coiled-coil spacer domain; (iii) a transmembrane domain; and (iv) an endodomain. The invention also provides a multimeric CAR formed by association of a plurality of CAR-forming polypeptides by virtue of association of their coiled-coil spacer domains.
    Type: Application
    Filed: March 22, 2016
    Publication date: February 22, 2018
    Inventors: Martin Pulé, Shaun Cordoba
  • Publication number: 20180050066
    Abstract: Compositions and methods are disclosed for improving the healing of surgical wounds, and specifically for improving the survival rate, color retention rate, density, and scarring rate of a hair follicular graft following a hair transplantation surgery. The composition may be a suspension for injection proximal to the surgical graft recipient site, with the suspension comprising 0.4-0.5 mL of a suspension of an autologous platelet solution of at least 1 billion platelets at a concentration exceeding 1.5 billion platelets per mL, about 20 mg of granulated extracellular matrix, and about 40 mg of triamcinolone acetonide.
    Type: Application
    Filed: August 8, 2017
    Publication date: February 22, 2018
    Inventor: Payam John Kahen
  • Publication number: 20180050067
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Application
    Filed: November 3, 2017
    Publication date: February 22, 2018
    Applicants: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Publication number: 20180050068
    Abstract: A method of treating or preventing cancer metastasis in a subject is described. The method includes implanting a decoy trap within the subject, the decoy trap comprising an implantable trap device including a metastatic cancer attractant. Methods of diagnosing cancer metastasis in a subject using the decoy traps are also described. The methods include implanting the decoy trap in the subject and allowing the decoy trap to remain within the subject for a period of time, and then diagnosing the subject as having metastatic cancer if metastatic cancer cells are detected in the decoy trap.
    Type: Application
    Filed: September 27, 2017
    Publication date: February 22, 2018
    Inventors: Diego Correa, Arnold I. Caplan
  • Publication number: 20180050069
    Abstract: The present invention discloses a method for treating and/or preventing metabolic syndrome and related diseases thereof, by administering a microbe composition to an individual to achieve the modulation of blood glucose, inhibition of body weight gain, reduction of low density cholesterol in blood, and reduction of hepatic expression of inflammatory factors, thereby effectively treating and/or preventing metabolic syndrome or related diseases thereof.
    Type: Application
    Filed: August 16, 2016
    Publication date: February 22, 2018
    Inventor: Chun-Ying WU
  • Publication number: 20180050070
    Abstract: The present invention relates to bacterial compositions and methods of use thereof. The bacterial compositions may include two or more bacteria of the genera Faecalibacterium, Lachnospira, Veillonella or Rothia. The bacterial compositions may be used in treating gut dysbiosis, asthma, allergy, or atopy, or altering the gut microbiota, or populating the gastrointestinal tract, in a subject in need thereof.
    Type: Application
    Filed: March 11, 2016
    Publication date: February 22, 2018
    Inventors: Brett FINLAY, Marie-Claire Arrieta, Shannon RUSSELL, Stuart TURVEY, Leah STIEMSMA
  • Publication number: 20180050071
    Abstract: An anti-age composition is described. The anti-age composition comprises a combination of antioxidant agents, such as flavonoids, anthocyanins, tannins, curcumin and derivatives thereof, as well as vitamins A, C and E, in association with Bifidobacteria and cell walls isolated from probiotics which takes into account all the different factors involved in the aging process in order to prevent or slow down the course thereof.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 22, 2018
    Inventor: Bernard BIZZINI
  • Publication number: 20180050072
    Abstract: A composition of Lactobacillus fermentum GMNL-296 and a use of Lactobacillus fermentum GMNL-296 for producing a composition to improve the infection symptoms of Clostridium difficile are provided. The Lactobacillus fermentum GMNL-296 is to promote the expression of anti-inflammatory cytokine IL-10 and Treg cell related transcription factors, so that the infection symptoms of weight loss and intestinal abnormalities are improved.
    Type: Application
    Filed: December 1, 2016
    Publication date: February 22, 2018
    Inventors: Yi-Hsing CHEN, Wan-Hua TSAI
  • Publication number: 20180050073
    Abstract: The present invention relates to a traditional Chinese medicine composition for treating prostate cancer and its preparation method and application. The composition is prepared from Ganoderma lucidum, Scutellaria baicalensis, Rabdosia rubescens, Panax notoginseng and Glycyrrhiza as raw materials in a weight ratio of 2-3:1-2:1-2:0.5-1.5:0.5-1.5 and prepared by mixed extraction or object extraction. The present inventions simplifies the prescription of the composition, is conducive to quality control, and reduces production cost, while the product curative effect remains unaffected, thus has a good application prospect.
    Type: Application
    Filed: July 20, 2016
    Publication date: February 22, 2018
    Inventor: Yihong Yang
  • Publication number: 20180050074
    Abstract: In preferred the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.
    Type: Application
    Filed: August 18, 2017
    Publication date: February 22, 2018
    Inventors: Scott Whitcup, Orest Olejnik, Michael Garst
  • Publication number: 20180050075
    Abstract: A therapeutic composition for skin use composed of essential oils derived from natural plant sources and at least one carrier oil. The compositions are administered topically to provide pain relief.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 22, 2018
    Inventors: Farah Kashefi, Arash Mojtabavi Naeini
  • Publication number: 20180050076
    Abstract: Kung Fu GU: a topical balm, circulatory, emollient, that helps accelerate the healing of Bruises, reduces swelling and pain as well as increasing circulation. Comprised of Grape seed oil, Bees wax, Rhubarb, Phellodendron, Safflower, Dandelion, Gardenia fruit, Skullcaps, Arnica Montana, Comfrey, Devil's claw, Frankincense, Myrrh, Dragon's Blood resin, Menthol crystals, Wintergreen oil, Birch oil, Lavender oil, Cajuput oil, Clove oil, and the method of preparing same said circulatory emollient balm.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 22, 2018
    Inventor: James Russell Prine
  • Publication number: 20180050077
    Abstract: Plasmonics-active metal nanostars are provided that can be used for treating and detecting cells in a subject. The modes of treatment include a photo-activated drug, which is activated by the photo-response of the nanostar to electromagnetic stimulation; a thermally-activated drug, which is activated by a thermal response of the nanostar to electromagnetic stimulation; and the thermal response of the nanostar itself to electromagnetic stimulation, which may directly or indirectly cause the death of an undesirable cell. Uptake of nanostars by undesirable cells may also aid in detection, by enhancing contrast or otherwise transforming electromagnetic stimulation during imaging.
    Type: Application
    Filed: October 17, 2017
    Publication date: February 22, 2018
    Inventors: Tuan Vo-Dinh, Hsiangkuo Yuan, Andrew Fales
  • Publication number: 20180050078
    Abstract: An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.
    Type: Application
    Filed: March 2, 2016
    Publication date: February 22, 2018
    Applicants: KOHJIN LIFE SCIENCES CO., LTD., PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, SAGA UNIVERSITY
    Inventors: Takaomi KESSOKU, Atsushi NAKAJIMA, Yoshio SUMIDA, Yuichiro EGUCHI, Susumu SAITO, Yusuke SAUCHI
  • Publication number: 20180050079
    Abstract: The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset.
    Type: Application
    Filed: April 3, 2017
    Publication date: February 22, 2018
    Inventor: Richard Franklin
  • Publication number: 20180050080
    Abstract: A composition for displacing loose skin and removing subcutaneous deposits of fatty tissue. The composition includes effective amounts of one or more bleomycin-type drugs that are operative to cause apoptosis in localized fat cells, thus causing permanent eradication of such cells. Loose skin is likewise displaced with dense fibrous tissue produced via selective scarring induced by the active bleomycin-type drugs. The compositions are formulated as creams, lotions, gels, waxes, foams, sprays and the like for selectively applied, local topical application, and may also be administered as a conventional transdermal patch. The compositions may alternatively be formulated to be injected into the skin.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 22, 2018
    Inventor: ADAM M. ROTUNDA
  • Publication number: 20180050081
    Abstract: A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject.
    Type: Application
    Filed: January 23, 2015
    Publication date: February 22, 2018
    Inventors: Peter S. N. Rowe, Aline Martin, Nicolae Valentin David, M. Laird Forrest, Kenneth Ryan Moulder, Shuang Cai, Daniel J. Aires
  • Publication number: 20180050082
    Abstract: The present invention relates to the use of serpins, including A1AT, its derivatives and analogs thereof, in the prevention or treatment of neuroinflammatory diseases. In particular embodiments, the invention relates to the combination of A1AT and another anti-inflammatory therapeutic compound. The present invention further relates to methods for administering said A1AT combination.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 22, 2018
    Applicant: Anvil Biosciences, LLC
    Inventors: Jack Tzu-Chiao Lin, Emily A. Stein
  • Publication number: 20180050083
    Abstract: The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject. Compositions and methods including a Nuclear Transport Modifier may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease in cholesterol and triglyceride levels in the blood and liver, a decrease in atherosclerotic lesion size, a decrease in body weight and in hyperglycemia, a reduction of fatty liver inflammation, and an improvement in liver function.
    Type: Application
    Filed: November 6, 2017
    Publication date: February 22, 2018
    Inventors: Jack J. Hawiger, Ruth Ann Veach, Jozef Zienkiewicz, Yan Liu, Robert D. Collins, Amy S. Major
  • Publication number: 20180050084
    Abstract: Methods and composition for delivery of enzymes to a subject's airway. In some aspects, nebulized composition of enzymes, such as plasminogen activators are provided. In further aspects perfluorocarbon compositions comprising enzymes, such as plasminogen activators are provided. Compositions may, in some aspects, be used for the treatment of lung infections or acute lung injury, such as inhalational smoke induced acute lung injury (ISALI).
    Type: Application
    Filed: February 26, 2016
    Publication date: February 22, 2018
    Inventors: Robert O. WILLIAMS, III, Steven IDELL, Sreerama SHETTY
  • Publication number: 20180050085
    Abstract: In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).
    Type: Application
    Filed: July 26, 2017
    Publication date: February 22, 2018
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
  • Publication number: 20180050086
    Abstract: Methods for improving the health of a female human or non-human animal are disclosed. The methods include the step of administering to the animal compositions including an effective amount of glycomacropeptide (GMP) for effectuating the methods. Specifically, the methods can be used to increase the rate of fat metabolism or fat oxidation, decrease percentage of body fat, increase the rate of bone mineralization, increase bone mineral content, increase bone mineral density, and/or increase bone strength in the animal. GMP-containing compositions can be used according to the disclosed methods to treat obesity and related metabolic conditions, or to treat or prevent osteoporosis, osteopenia, and other conditions related to loss of bone mineral content or bone strength.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 22, 2018
    Inventors: Denise M. Ney, Eric Chi-Liang Yen, David W. Nelson, Patrick Solverson
  • Publication number: 20180050087
    Abstract: Provided herein are methods and compositions for treating lipodystrophy using fibroblast growth factor 1 (FGF-1) compounds.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 22, 2018
    Applicants: Salk Institute for Biological Studies, Metacrine, Inc.
    Inventors: Neil McDonnell, Ronald M. Evans, Michael Downes
  • Publication number: 20180050088
    Abstract: The present invention encompasses ophthalmic compositions that may be used for various conditions of the eye, and particularly, conditions of the cornea. Also encompassed are methods that utilise these compositions and kits that include these compositions.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Inventors: Colin GREEN, Carol Ann GREENE, Trevor SHERWIN
  • Publication number: 20180050089
    Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
    Type: Application
    Filed: July 14, 2017
    Publication date: February 22, 2018
    Inventors: Ravindra Kumar, John Knopf
  • Publication number: 20180050090
    Abstract: The present invention comprises pegylated TRAIL peptides and their use in conjunction with various TRAIL sensitizing agents in tumor homing nanoparticle formulations for use in the treatment of cancer in a subject.
    Type: Application
    Filed: March 15, 2016
    Publication date: February 22, 2018
    Inventors: Seulki Lee, Martin G. Pomper, Magdalena Swierczewska, Yumin Oh
  • Publication number: 20180050091
    Abstract: The present invention provides methods of modulating of cancer immunity using type 2 innate lymphoid cells (IL-C2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are methods of preventing tumor metastasis and/or cancer progression by treatment with therapies comprising type 2 innate lymphoid cells (ILC2s), interleukin 33 (IL-33), IFI44 or combination thereof. Also provided are diagnostic methods for assessing cancer prognosis.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 22, 2018
    Inventor: Wilfred JEFFERIES
  • Publication number: 20180050092
    Abstract: The present invention relates to a CD4+ T cell that produces high levels of IL-10 for use in the treatment and/or prevention of a tumor that expresses CD13, HLA-class I and CD54 and/or for use in inducing Graft versus tumour (GvT). The present invention relates also to a composition comprising said cell and to a method to select a subject to be treated with said cell.
    Type: Application
    Filed: March 11, 2016
    Publication date: February 22, 2018
    Applicants: FONDAZIONE TELETHON, OSPEDALE SAN RAFFAELE SRL, FONDAZIONE CENTRO SAN RAFFAELE
    Inventors: Silvia Adriana GREGORI, Maria Grazia RONCAROLO
  • Publication number: 20180050093
    Abstract: A leptin active peptide having helix D region mutation, a coding gene thereof, and an application thereof are provided in the present invention. An amino acid sequence of the leptin active peptide having helix D region mutation is shown in SEQ ID NO. 1.
    Type: Application
    Filed: November 6, 2017
    Publication date: February 22, 2018
    Inventors: LIHONG YUAN, JIAHAI LU, BENFU LIN
  • Publication number: 20180050094
    Abstract: A leptin active peptide having CD-loop and helix E region mutations, a coding gene thereof, and an application thereof are provided in the present invention. An amino acid sequence of the leptin active peptide having CD-loop and helix E region mutations is shown in SEQ ID NO.1.
    Type: Application
    Filed: November 6, 2017
    Publication date: February 22, 2018
    Inventors: LIHONG YUAN, JIAHAI LU, BENFU LIN
  • Publication number: 20180050095
    Abstract: This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof.
    Type: Application
    Filed: March 8, 2017
    Publication date: February 22, 2018
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Doris Stoffers, Diva D. DE LEON, Charles STANLEY
  • Publication number: 20180050096
    Abstract: A pharmaceutical composition for use in the treatment of hypoparathyroidism by oral administration of the composition is provided herein. The composition comprises parathyroid hormone or a fragment thereof; and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate). Further disclosed are uses of the composition in the preparation of a medicament and methods of treating hypoparathyroidism utilizing the composition.
    Type: Application
    Filed: February 9, 2016
    Publication date: February 22, 2018
    Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
  • Publication number: 20180050097
    Abstract: This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation component and a microtubule-associated tau protein (MAPT) component linked to at least a portion of the antigen presentation component. This disclosure describes, in another aspect, a transgenic mouse. Generally, the transgenic mouse possesses brain cells that have a polynucleotide that encodes human microtubule-associated protein tau (MAPT). The polynucleotide further exhibits a deletion of at least a portion of endogenous mouse MAPT. The transgenic mouse also includes a forebrain neuron-specific deletion of a polynucleotide that encodes Myeloid Differentiation Primary Response Gene 88 (MyD88). In a further aspect, this disclosure describes a method of producing the transgenic mouse.
    Type: Application
    Filed: March 25, 2016
    Publication date: February 22, 2018
    Inventors: Kiran Bhaskar, Nicole Maphis, David S. Peabody, Bryce Chackerian, Julianne Peabody, Erin Crossey
  • Publication number: 20180050098
    Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 22, 2018
    Inventor: Bruce W. LYDAY
  • Publication number: 20180050099
    Abstract: The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen.
    Type: Application
    Filed: October 10, 2017
    Publication date: February 22, 2018
    Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
  • Publication number: 20180050100
    Abstract: The present invention discloses a Salmonella Paratyphi A with an O-antigen having an extended carbohydrate chain and uses thereof. The method comprises the following steps: inactivating an cld gene encoding an enzyme controlling chain length of O-antigen of a Salmonella paratyphi A strain to obtain a Salmonella paratyphi A with deletion of cld gene; allowing overexpression of cldLT2 gene encoding an enzyme controlling chain length of O-antigen of Salmonella typhimurium in Salmonella paratyphi A deficient in the cld gene encoding an enzyme controlling chain length of O-antigen, so as to extend carbohydrate chain length of O-antigen. Both of the Salmonella paratyphi A O-polysaccharide-recombinant fusion protein conjugate vaccines rCTB45733-OPSSpty50973 and rEPA4573-OPSSpty50973 as prepared by using Salmonella Paratyphi A with an O-antigen having an extended carbohydrate chain can induce mice to generate specific antibodies against Salmonella paratyphi A, and their antibody titers are significantly improved.
    Type: Application
    Filed: September 7, 2015
    Publication date: February 22, 2018
    Applicant: Institute of Biotechnology, Academy of Military Medical Sciences, China
    Inventors: Jun WU, Peng SUN, Bo LIU, Shaohong CHANG, Xin GONG, Hengliang WANG, Li ZHU, Chao PAN, Erling FENG
  • Publication number: 20180050101
    Abstract: The present application provides methods and uses of O-oligosaccharyltransferase (O-OTases) for generating vaccines. In particular, the present application provides a method of synthesizing a glycoprotein comprising glycosylation of pilin-like protein ComP using a Pg1LComP O-OTase. Uses of glycoproteins synthesized by glycosylating ComP using Pg1LComP O-OTase, particularly for the preparation of vaccines and the like, including a vaccine to Streptococcus, is also provided.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 22, 2018
    Applicant: VAXNEWMO LLC
    Inventors: Mario FELDMAN, Mohamed Adel NASR
  • Publication number: 20180050102
    Abstract: Complexes suitable for targeting and killing a human target cell comprising a first polypeptide with a binding structure for binding the complex to the cellular surface receptor CD89 (e.g. with an anti CD89 antibody) presented on the cell surface of the human target cell and a second polypeptide comprising a toxic effector domain, preferably Pseudomonas exotoxin A); to nucleic acid molecules encoding said complexes, vectors, host cells containing the nucleic acids and methods for preparation and producing such complexes; compositions and methods for using said complexes for the treatment of diseases, in particular of cancer diseases like leukemia.
    Type: Application
    Filed: March 25, 2015
    Publication date: February 22, 2018
    Inventors: Christoph Stein, Radoslav Mladenov, Bernhard Stockmeyer, Stefan Barth, Lea Christin Hein, Rainer Fischer
  • Publication number: 20180050103
    Abstract: Disclosed is a method of preventing or treating a condition of the gastrointestinal tract. The method includes the steps of providing a DNA repair composition, the DNA repair composition comprising at least one DNA repair enzyme, the DNA repair composition configured for administration within the gastrointestinal tract of a patient; and administering the DNA repair composition to the patient, such that the DNA repair composition is absorbed within the gastrointestinal tract of the patient to treat the condition of the gastrointestinal tract.
    Type: Application
    Filed: April 14, 2017
    Publication date: February 22, 2018
    Inventor: Ronald L. Moy
  • Publication number: 20180050104
    Abstract: The present disclosure concerns a digital corneal crosslinking technology for adjusting the corneal curvature, comprising the following steps: administering in drops a composition comprising a photoinitiator compound to the corneal stromal of the subject, locally irradiating the corneal by utilizing digital micromirror device controlled by computer. The corneal curvature can be adjusted totally or locally. The invention also discloses an apparatus for the digital corneal crosslinking. The method and apparatus is minimum invasive and can be used to accurately and efficiently adjust the corneal curvature.
    Type: Application
    Filed: November 15, 2016
    Publication date: February 22, 2018
    Inventors: TAO XIE, JINGJUN WU, QIAN ZHAO, LIMEI HUANG
  • Publication number: 20180050105
    Abstract: The invention concerns a method of generating an immune response in a subject, comprising administering to the subject an antigenic molecule, a photosensitizing agent, a checkpoint inhibitor, and irradiating said subject with light of a wavelength effective to activate the photosensitizing agent to generate an immune response. Preferably the method is a method of vaccination. The invention also provides related methods, compositions, cells, uses, products and kits.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Applicant: PCI Biotech AS
    Inventor: Anders HØGSET
  • Publication number: 20180050106
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
    Type: Application
    Filed: October 30, 2017
    Publication date: February 22, 2018
    Inventor: Herriot Tabuteau
  • Publication number: 20180050107
    Abstract: Provided herein are compositions comprising neurosteroids and saponins, methods of making said compositions, and methods of utilizing said compositions to treat or prevent perinatal depression (PND) in a subject in need thereof.
    Type: Application
    Filed: August 15, 2017
    Publication date: February 22, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Thomas M DiMauro, Kevin Wildenhaus, Michael J Fevola, Tobias Johannes Fuetterer
  • Publication number: 20180050108
    Abstract: The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a beneficial salt of a luteinizing hormone releasing hormone (LHRH) analogue formed with a strong acid that minimizes or prevents the interaction/reaction between the LHRH and the polymer in an organic solution; b) a biodegradable polymer; c) a pharmaceutically acceptable organic solvent; and d) optionally one or more excipients. The present invention also relates to a method of manufacturing and a method of use thereof.
    Type: Application
    Filed: July 27, 2017
    Publication date: February 22, 2018
    Inventors: Yuhua Li, Benjamin Chien
  • Publication number: 20180050109
    Abstract: The present application relates to silk fibroin-based materials, methods for making and using the same. Provided materials exhibit shape memory characteristics while showing comparable or better volumetric swelling, biocompatibility and/or degradability when compared to current memory polymers derived from either natural or synthetic materials.
    Type: Application
    Filed: March 11, 2016
    Publication date: February 22, 2018
    Inventors: David L. Kaplan, Fiorenzo G. Omenetto, Joseph E. Brown, Rodrigo R. Jose
  • Publication number: 20180050110
    Abstract: This invention relates to a complex for cancer cell chemotherapy and, more particularly, to a HER2 aptamer-anticancer drug complex for chemotherapy of cancer cells, which includes a nucleic acid aptamer specifically binding to HER2 and an anticancer drug linked with the nucleic acid aptamer, so that HER2-positive breast cancer cells are selectively targeted and killed.
    Type: Application
    Filed: August 16, 2016
    Publication date: February 22, 2018
    Inventors: Jae-Hong SEO, Chang-Ill BAN, Hun-Ho Jo, Ji-Young KIM, Young-Kwan CHO